GSK/$GSK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GSK
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
$GSK
Sector
Primary listing
NYSE
Employees
68,629
Headquarters
Website
GSK Metrics
BasicAdvanced
$88B
40.03
$1.10
0.29
$1.62
3.83%
Price and volume
Market cap
$88B
Beta
0.29
52-week high
$45.59
52-week low
$31.72
Average daily volume
5.4M
Dividend rate
$1.62
Financial strength
Current ratio
0.867
Quick ratio
0.555
Long term debt to equity
106.618
Total debt to equity
120.9
Dividend payout ratio (TTM)
72.80%
Interest coverage (TTM)
10.25%
Profitability
EBITDA (TTM)
12,402.556
Gross margin (TTM)
71.69%
Net profit margin (TTM)
10.82%
Operating margin (TTM)
20.13%
Effective tax rate (TTM)
13.80%
Revenue per employee (TTM)
$614,050
Management effectiveness
Return on assets (TTM)
6.78%
Return on equity (TTM)
28.33%
Valuation
Price to earnings (TTM)
40.029
Price to revenue (TTM)
4.264
Price to book
4.48
Price to tangible book (TTM)
-9.05
Price to free cash flow (TTM)
27.838
Free cash flow yield (TTM)
3.59%
Free cash flow per share (TTM)
1.586
Dividend yield (TTM)
3.67%
Forward dividend yield
3.83%
Growth
Revenue change (TTM)
0.59%
Earnings per share change (TTM)
-15.48%
3-year revenue growth (CAGR)
4.37%
10-year revenue growth (CAGR)
3.09%
3-year earnings per share growth (CAGR)
-9.68%
10-year earnings per share growth (CAGR)
-10.43%
3-year dividend per share growth (CAGR)
-9.94%
10-year dividend per share growth (CAGR)
-4.52%
What the Analysts think about GSK
Analyst ratings (Buy, Hold, Sell) for GSK stock.
Bulls say / Bears say
GSK expects full-year sales and profit at the top of its 2025 guidance after Q2 results showed a 6% increase in turnover to nearly £8 billion and adjusted EPS of 46.5 pence, beating forecasts and demonstrating strong operations (Reuters)
The Jiangsu Hengrui deal gives GSK global rights to HRS-9821 for COPD, plus 11 early-stage programs in oncology, respiratory, immunology, and inflammation, with $500 million upfront and up to $12 billion in milestones. This meaningfully strengthens GSK’s pipeline (Reuters)
The EMA has accepted GSK’s application to expand its RSV vaccine Arexvy to adults 18 and over, potentially opening up a larger market in a field expected to reach $10 billion. This supports vaccine sales recovery, with a decision expected in H1 2026 (Reuters)
Analysts expect GSK will generate only £34 billion in revenue by 2031, which is 15% lower than its £40 billion target. This increases the chance of dilutive M&A deals or asset write-downs to make up the gap (Reuters Breakingviews)
Dolutegravir, which drives four of GSK’s HIV regimens and delivered over £5 billion in sales, will lose its U.S. patent protection in 2028. This will expose the group to significant generic competition and put pressure on cash flow (Reuters Breakingviews)
Dynavax’s experimental shingles vaccine Z-1018 produced an immune response comparable to Shingrix but caused injection-site reactions in just 12.5% of recipients, compared to Shingrix’s 52.6%. This poses a significant competitive threat to GSK’s leading vaccine (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
GSK Financial Performance
Revenues and expenses
GSK Earnings Performance
Company profitability
GSK News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GSK stock?
GSK (GSK) has a market cap of $88B as of October 16, 2025.
What is the P/E ratio for GSK stock?
The price to earnings (P/E) ratio for GSK (GSK) stock is 40.03 as of October 16, 2025.
Does GSK stock pay dividends?
Yes, the GSK (GSK) stock pays dividends to shareholders. As of October 16, 2025, the dividend rate is $1.61919 and the yield is 3.83%. GSK has a payout ratio of 72.8% on a trailing twelve-month basis.
When is the next GSK dividend payment date?
The next GSK (GSK) dividend payment date is unconfirmed.
What is the beta indicator for GSK?
GSK (GSK) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.